Evidence map›Paper›PMID 32628270›Full record

ArticleThe British journal of dermatology2020

Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing.

L Le Cleach, L Dousset, H Assier, S Fourati, S Barbarot, C Boulard, C Bourseau Quetier, L Cambon, C Cazanave, A Colin and 12 more

Open access · bronzeAbstract read
In one paragraph

Article in The British journal of dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 4 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Pandemic chilblains: Are they SARS-CoV-2-related or not?Clinical immunology (Orlando, Fla.) · 2022
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 1 country.

L Le CleachDermatology Department, Hôpital Henri Mondor, Créteil, France.ORCID 0000-0003-1385-6839
L DoussetDermatology Department, University Hospital Bordeaux, Bordeaux, France.
H AssierDermatology Department, Hôpital Henri Mondor, Créteil, France.ORCID 0000-0003-0465-1241
S FouratiDepartment of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.
S BarbarotDepartment of Dermatology, Nantes Université, CHU Nantes, UMR 1280 PhAN, INRAE, F-44000, Nantes, France.ORCID 0000-0002-6629-9100
C BoulardLe Havre Hospital, Department of Dermatology, 76600, Le Havre, France.
C Bourseau QuetierPrivate Practice, rue Jules Ferry, Blanquefort, France.
L CambonPrivate Practice, rue de la Balance, Toulouse, France.
C CazanaveInfectious Diseases, University Hospital Bordeaux, Bordeaux, France.
A ColinDermatology Department, Hôpital Henri Mondor, Créteil, France.
E KostrzewaDermatology Department, Hôpital Robert Boulin, Libourne, France.
C LesortDepartment of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
A Levy RoyPrivate Practice, Avenue du Général de Gaulle, 13410, Lambesc, France.
F LombartDermatology, Amiens University Hospital Centre, Amiens, France.
J Marco-BonnetPrivate practice, Avenue Pierre Brossolette 92120, Montrouge, France.
J-B MonfortSorbonne Université, Paris, France.ORCID 0000-0002-4792-2622
M SamimiDermatology Department, University Hospital of Tours, ISP1282 INRA-University of Tours, Tours, France.ORCID 0000-0001-6742-9088
M TardieuDermatology Department, Centre Hospitalier Universitaire Grenoble Alpes, 38700, La Tronche, France.
P WolkensteinDermatology Department, Hôpital Henri Mondor, Créteil, France.
E SbidianDermatology Department, Hôpital Henri Mondor, Créteil, France.ORCID 0000-0002-1267-5270
M Beylot-BarryDermatology Department, University Hospital Bordeaux, Bordeaux, France.ORCID 0000-0001-6150-1229
French Society of Dermatology
Bordeaux Population Health · FRHôpitaux Universitaires Henri-Mondor · FRUniversité Paris-Est Créteil · FRCentre Hospitalier Universitaire Amiens-Picardie · FRCentre Hospitalier Universitaire de Grenoble · FRGénérale de Santé · FRHospices Civils de Lyon · FRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FRUniversité de Tours · FRUniversité Jean Moulin Lyon III · FRUniversité Le Havre Normandie · FRUniversité Sorbonne Nouvelle · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcral lesions, mainly chilblains, are the most frequently reported cutaneous lesions associated with COVID-19. In more than 80% of patients tested, nasopharyngeal swabs were negative on reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 when performed, and serology was generally not performed.

methodsA national survey was launched on 30 March 2020 by the French Society of Dermatology asking physicians to report cases of skin manifestations in patients with suspected or confirmed COVID-19 by using a standardized questionnaire. We report the results for acral manifestations.

resultsWe collected 311 cases of acral manifestations [58.5% women, median age 25.7 years (range 18-39)]. The most frequent clinical presentation (65%) was typical chilblains. In total, 93 cases (30%) showed clinical suspicion of COVID-19, 67 (22%) had only less specific infectious symptoms and 151 (49%) had no clinical signs preceding or during the course of acral lesions. Histology of skin biopsies was consistent with chilblains. Overall, 12 patients showed significant immunological abnormalities. Of the 150 (48%) patients who were tested, 10 patients were positive. Seven of 121 (6%) RT-PCR-tested patients were positive for SARS-CoV-2, and five of 75 (7%) serology-tested patients had IgG anti-SARS-CoV-2. Tested/untested patients or those with/without confirmed COVID-19 did not differ in age, sex, history or acral lesion clinical characteristics.

conclusionsThe results of this survey do not rule out that SARS-CoV-2 could be directly responsible for some cases of chilblains, but we found no evidence of SARS-CoV-2 infection in the large majority of patients with acral lesions during the COVID-19 lockdown period in France. What is already known about this topic? About 1000 cases of acral lesions, mainly chilblains, were reported during the COVID-19 outbreak. Chilblains were reported to occur in young people within 2 weeks of infectious signs, which were mild when present. Most cases did not have COVID-19 confirmed by reverse transcription polymerase chain reaction (RT-PCR), and few serology results were available. What does this study add? Among 311 patients with acral lesions, mainly chilblains, during the COVID-19 lockdown period in France, the majority of patients tested had no evidence of SARS-CoV-2 infection. Overall, 70 of 75 patients were seronegative for SARS-Cov-2 serology and 114 of 121 patients were negative for SARS-CoV-2 RT-PCR.

Indexed as

AdolescentAdultBetacoronavirusBiopsyChilblainsClinical Laboratory TechniquesCoronavirus InfectionsCOVID-19COVID-19 TestingFemaleFranceHumansMalePandemicsPneumonia, ViralPolymerase Chain ReactionRNA, Viral

Identifiers

PMID32628270
PMCPMC7361395
OpenAlexW3038792410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.